1,577 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
AMGN Amgen Inc. $200.81 $129.98B Uptrend
Article Searches
5 Blue Chips That Offer Great Buy-Write Opportunities https://seekingalpha.com/article/4231895-5-blue-chips-offer-great-buy-write-opportunities?source=feed_all_articles Jan 07, 2019 - If done consistently and properly, options are wonderful tools to generate reliable monthly income. No matter what type of investor you are, the following option strategies can be used for various pur
What The Celgene Deal Means For The Biotech Sector https://seekingalpha.com/article/4231701-celgene-deal-means-biotech-sector?source=feed_sector_healthcare Jan 07, 2019 - On Jan. 3, pharma giant Bristol-Myers Squibb announced its intention to acquire Celgene, one of the largest biotech companies in the world, for $74 billion; the deal awaits shareholder approval.The bu
Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan http://www.zacks.com/stock/news/345648/merck-buys-nash-candidate-keytruda-wins-5-approvals-in-japan?cid=CS-ZC-FT-345648 Jan 04, 2019 - Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar http://www.zacks.com/stock/news/345603/teva-teva-ends-dispute-with-amgen-over-generic-sensipar?cid=CS-ZC-FT-345603 Jan 03, 2019 - Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.
Stocks making the biggest moves premarket: AAPL, CELG, JNJ, UBS & more https://www.cnbc.com/2019/01/03/stocks-making-the-biggest-moves-premarket-aapl-celg-jnj-ubs--more.html Jan 03, 2019 - Names on the move ahead of the open.
The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen http://feeds.benzinga.com/~r/benzinga/~3/G8y-HlX2EJA/the-daily-biotech-pulse-aevis-adhd-drug-flunks-mid-stage-trial-bristo Jan 03, 2019 -

Here's a roundup of top developments in the biotech space over the last 24 hours.

read more

5 Buffett-Munger Stocks Producing High Gains for 2018 http://www.gurufocus.com/news/792902/5-buffettmunger-stocks-producing-high-gains-for-2018 Dec 31, 2018 - 5 Buffett-Munger Stocks Producing High Gains for 2018, Stocks: USNA,DORM,AZO,TSCO,AMGN,BRK.A,BRK.B, Warren Buffett, release date:Dec 31, 2018
Is Arrowhead The Biotech Play You've Been Waiting For? https://seekingalpha.com/article/4230817-arrowhead-biotech-play-waiting?source=feed_sector_healthcare Dec 31, 2018 - Arrowhead’s recent agreement with Janssen Pharmaceuticals further validates both new TRiM Platform and ARO-HBV program.The deal allows funding for the next 6 to 8 years of Arrowhead’s operations.Pre-c
'Safer Dividend Picks From Barron's 10 For 2019 And Kiplinger's 12 Forever Stocks https://seekingalpha.com/article/4230525-safer-dividend-picks-barrons-10-2019-kiplingers-12-forever-stocks?source=feed Dec 28, 2018 - The December 17 issue of Barron's featured 10 favorite picks for the year ahead. While Kiplinger Today December 21 proclaimed 12 Stocks You Should Never Sell. This shows 'safer' picks.Of the 22 equiti
Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis http://www.zacks.com/stock/news/345011/spectrum-pharma-files-bla-for-neutropenia-candidate-rolontis?cid=CS-ZC-FT-345011 Dec 28, 2018 - Spectrum Pharma (SPPI) petitions for a BLA to the FDA regarding its lead pipeline candidate, Rolontis, to address chemotherapy-induced neutropenia in patients with breast cancer.

Pages: 1234567...158

<Page 2>